Akcea Therapeutics (NASDAQ:AKCA) had its target price decreased by Stifel Nicolaus from $33.00 to $25.00 in a research note released on Tuesday. Stifel Nicolaus currently has a hold rating on the stock.

A number of other research firms also recently issued reports on AKCA. Zacks Investment Research upgraded Akcea Therapeutics from a hold rating to a buy rating and set a $29.00 price target on the stock in a research note on Tuesday, May 1st. BidaskClub downgraded Akcea Therapeutics from a buy rating to a hold rating in a research note on Thursday, May 10th. Wells Fargo & Co lifted their target price on Akcea Therapeutics from $33.00 to $46.00 and gave the company an outperform rating in a research note on Tuesday, August 7th. BMO Capital Markets lowered their target price on Akcea Therapeutics from $42.00 to $38.00 and set an outperform rating on the stock in a research note on Friday, May 4th. Finally, UBS Group downgraded Akcea Therapeutics from a buy rating to a hold rating in a research note on Wednesday, August 8th. Five analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average price target of $35.00.

NASDAQ:AKCA opened at $24.73 on Tuesday. The company has a market cap of $2.80 billion and a P/E ratio of -11.04. Akcea Therapeutics has a 52-week low of $15.20 and a 52-week high of $40.75.

Akcea Therapeutics (NASDAQ:AKCA) last released its quarterly earnings results on Monday, August 6th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.32. The firm had revenue of $18.30 million for the quarter, compared to the consensus estimate of $14.24 million. Akcea Therapeutics had a negative return on equity of 58.32% and a negative net margin of 192.97%. The firm’s quarterly revenue was up 221.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.41) EPS. analysts expect that Akcea Therapeutics will post -1.91 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the business. Quantbot Technologies LP purchased a new stake in shares of Akcea Therapeutics in the first quarter valued at approximately $104,000. MetLife Investment Advisors LLC purchased a new stake in shares of Akcea Therapeutics in the fourth quarter valued at approximately $199,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Akcea Therapeutics in the first quarter valued at approximately $201,000. Paloma Partners Management Co purchased a new stake in shares of Akcea Therapeutics in the second quarter valued at approximately $216,000. Finally, Barclays PLC boosted its stake in shares of Akcea Therapeutics by 375.7% in the first quarter. Barclays PLC now owns 11,312 shares of the company’s stock valued at $290,000 after buying an additional 8,934 shares in the last quarter. Institutional investors own 26.58% of the company’s stock.

Akcea Therapeutics Company Profile

Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.

Featured Story: Asset Allocation

Analyst Recommendations for Akcea Therapeutics (NASDAQ:AKCA)

Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.